Lupin receives tentative FDA approval for generic Locoid Lotion
13 February 2018 | News
It is indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older
Pharma major Lupin has announced the tentative approval for its Hydrocortisone Butyrate Lotion, 0.1% from the United States Food and Drug Administration (FDA) to market a generic version of Precision Dermatology, Inc.’s Locoid® Lotion, 0.1%.
Lupin’s Hydrocortisone Butyrate Lotion, 0.1% is the generic equivalent of Precision Dermatology, Inc.’s Locoid® Lotion, 0.1%.
It is indicated for the topical treatment of mild to moderate atopic dermatitis in patients 3 months of age and older.
Hydrocortisone Butyrate Lotion, 0.1% had annual sales of approximate USD 16.1millionin the US (IQVIA MAT October 2017).
